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Objective: The objective was to describe the endometrial milieu of stable transplant patients and healthy women before and after
levonorgestrel intrauterine system (LNG-IUS) insertion.
Study design: Women between 18 and 45 years of age desiring LNG-IUS insertion were enrolled with a 2:1 ratio of healthy to stable solid
organ transplant patients. The first visit entailed a blood draw, uterine lavage and endometrial biopsy followed by LNG-IUS insertion.
Follow-up visit involved a repeat serum draw, uterine lavage and endometrial biopsy. Cytokine levels were measured in the uterine lavage
and serum by quantifying inflammatory biomarkers. Immunohistochemistry staining was performed on the endometrial tissue to measure
macrophage levels. Statistical analysis included a nonparametric analysis that compared medians of the marker levels before and after
intrauterine device (IUD) insertion within the group and between the two groups.
Results: Sixteen participants completed the study: 5 solid organ transplant patients and 11 healthy patients. For the serum, there were no
marked changes in the cytokines or soluble receptor levels in either group after IUD insertion. However, in the uterine lavage, there was an
increase in cytokine levels post-IUD insertion for both healthy and transplant women. For the endometrial tissue, there was evidence of
macrophage activity in both groups after device insertion.
Conclusions: This pilot study investigated the uterine environment of the transplant patient population. Findings have pointed to the strong
local inflammatory response following LNG-IUS insertion for the transplant recipients. In addition, these preliminary findings will help
power a larger study that can investigate the safety and effectiveness of the IUD in this patient population.
Implications: Findings from this pilot study suggest that the IUD is inducing a local inflammatory reaction in the uterus of the transplant
patient as in the healthy control. A larger study can build on these preliminary results to pursue the efficacy and safety of IUD use among
solid organ transplant patients.
©2016TheAuthors. PublishedbyElsevier Inc. This is an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Keywords: Intrauterine device; Immunology; Transplant; Endometrium1. Introduction
Limited data exist on the use of intrauterine contraception
in women who require chronic immunosuppression, such as
solid organ transplant (SOT) recipients. Pregnancy during an
immunosuppressed state has the potential for serious
morbidity, secondary to worsening of maternal health⁎ Corresponding author.
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[1]. Providing reliable, long-term contraception for these
women is important for themorbidity associatedwith unplanned
pregnancy. However, practitioners are reticent to provide
intrauterine devices (IUDs) for SOT recipients in the absence
of studies revealing not only the safety and effectiveness of
IUDs but their mechanism of action and effects on immune/
inflammatory biomarkers in this select group.
Investigations on the IUD's mechanism of action have
centered on the healthy, immunocompetent endometrium.
These studies revolve around the local inflammatory reaction
with the IUD. Macrophages, neutrophils and plasma cellsnder theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[2–6]. In turn, the macrophages produce various cytokines
that further trigger the inflammatory response. Therefore,
macrophages and cytokines are our players of interest in
this study.
Macrophages are present in the endometrium with an
active IUD in place [4,7]. The levonorgestrel (LNG)-IUD
remodels the endometrium with stromal cell decidualization
and has been associated with the marked presence of
neutrophils and macrophages. [8] An earlier study has also
highlighted the endometrial changes with elevated leuco-
cytes and tissue IL-8 levels 1 month after LNG-IUD
insertion [7].
Another approach to studying the endometrial environ-
ment is investigating the infiltrates surrounding and attach-
ing to the IUD. One study demonstrated attachment of
leucocytes to the IUD, and these cells produced prostaglan-
dins, contributing to the inflammatory response [9].
Although this study focused on the inert IUD, there have
been subsequent studies following the same idea by
performing a uterine lavage to examine cells on the device
[10]. Given these findings, we quantified biomarker levels
through uterine lavage and endometrial sampling.
There were several studies that informed the selection of
cytokines in this study. One study reported the endometrial
tissue and fluid in postmenopausal women with an IUD and
found that there was an increase in IL-6 and TNF-α in the
endometrium with the IUD in place [10]. Another noted
IL-1α, IL-1β and IL-6 as products of the macrophages and T
lymphocytes in their evaluation of endometrium [3]. We
were also curious to investigate the macrophage subtypes 1
and 2 (M1 and M2) due to their distinct properties. M1s are
proinflammatory cells that produce proinflammatory cyto-
kines (IL-6, TNF-α, IL-23), whereas the M2s have
anti-inflammatory properties, producing IL-10 [11].
Before investigating the safety and effectiveness of the
IUD in the SOT group, there has to be an understanding of
the IUD's effects on the endometrium in this population. The
main objective of this study was to investigate the uterine
environment of both the transplant patient and healthy
controls by examining the histology and inflammatory
markers, focusing on the macrophage with its subtypes.
Our hypotheses were the following: (a) Transplant patients
would display a smaller difference in endometrial inflam-
matory markers after IUD insertion compared to the healthy
controls, and (2) proinflammatory macrophages (type 1
macrophages) would predominate in the healthy women,
while anti-inflammatory macrophages (type 2 macrophages)
would predominate in the transplant patient.2. Materials and methods
2.1. Study participants
We recruited women between the ages of 18 to 45 years
interested in the LNG-IUD as a birth control method.Inclusion criteria for the healthy controls included no
immunosuppressive drug use in the past 3 months and no
contraindications to IUD insertion. Exclusion criteria were
current pregnancy, current pelvic infection and known to be
HIV positive. For the SOT patient, we applied similar
inclusion/exclusion criteria in addition to the criterion of
being stable on her immunosuppressant regimen. We aimed
for a case: control ratio of 1:2. After establishing eligibility,
we reviewed and signed appropriate consents with the
participants. We obtained the Institutional Review Board
approval prior to study initiation.
2.2. Study visits
The study consisted of two visits. Visit 1 for both the SOT
and healthy patients started with a blood draw by using a BD
Vacutainer Serum collector. To exclude those with any local
infections, we performed gonorrhea and chlamydia (GC/CT)
cultures on all patients prior to IUD insertion per clinic
protocol. The SOT patients had a prescreening visit that
entailed contraceptive counseling and STD screening
including HIV and rapid plasma reagin testing, GC/CT
cultures and wet mounts. Prior to IUD insertion, we
performed a uterine lavage followed by an endometrial
biopsy (EMB). For the uterine lavage, we inserted a saline
sonohysterography catheter through the cervix. We then
pushed 3 ml of sterile normal saline through the catheter and
withdrew the wash contents using a syringe. We performed
the lavage under ultrasound guidance to ensure proper
placement of the catheter in the uterine cavity. We avoided
placement in the cervical canal to minimize withdrawal of
cervicovaginal secretions. In addition, the reason to perform
the lavage prior to the EMB was to minimize blood
contamination of the wash that an EMB could induce if
performed first. For the EMB, we used a Pipelle to withdraw
endometrial tissue with a maximum of three passes.
The study participant returned 4–6 weeks later for visit 2.
The participants completed a five-question exit survey at this
visit. We took a repeat blood draw. Then we performed a
uterine lavage and endometrial biopsy while keeping the
IUD in place.
2.3. Immunoassay of cytokines and soluble receptors in
serum and lavage fluids
We transported serum and lavage samples to the lab within
2 h of collection. We centrifuged the fluid sample and then
subaliquoted the supernatant and serum into microtubes.
The assays used in this study were two multiplexed
immunometric assay panels (Luminex platform) for cyto-
kines (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-γ) and for
soluble receptors (sIL-2R, sIL-6R, sTNFR2 and sCD14)
(R&D Systems). The Luminex xMAP system uses spectrally
addressed bead sets, each of which is conjugated with a
different capture monoclonal antibody specific for a given
target molecule. The antibody-conjugated beads react with
the sample and a secondary detection antibody to form a
Table 1
Baseline characteristics of the healthy controls and SOT women
Healthy (n=11) Transplant (n=5)
Age range 19–38 20–38
Mean age 27.6 years 29.4 years
Median age 27 years 30 years
Parity Nulliparous (n=9) Nulliparous (n=5)
Ethnicity Hispanic (n=1) Hispanic (n=3)
Asian (n=1) African American (n=1)
African American(n=2) White (n=1)
White (n=7)
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assay, the Bio-Plex 200 Luminex array reader (BioRad)
quantifies the amount of each analyte in the assay solution.
The intraassay variations were b12%. The interassay
coefficients of variance were the following: 19.95 (IL-6),
9.32 (IL-8), 27.28 (IL-10), 17.81 (TNF-α), 25.69 (IFN-γ),
25.26 (IL-1β), 6.86 (CD14), 4.88 (TNF), 3.73 (IL-6) and
7.96 (IL-2). Reporting of the cytokines was in pg/ml.
2.4. Immunohistochemistry of endometrial tissue
For the endometrial tissue samples, we prepared hema-
toxylin and eosin stains for pathology interpretation. We
studied several markers for the immunohistochemical (IHC)
staining. M1 macrophages phenotypically express CD16 and
CD86, whereas M2s express arginase and CD206. [11,12]
Additionally, we included cytokines that these subtypes
release. M1 cells secrete IL-6, IL-8, IFN-γ and TNF-α, and
M2 cells secrete IL-4 and IL-10 [13,14].
For IHC staining, we prepared the slides in a process that
involved deparaffinization, incubation and a wash. For stain
visualization, we incubated the slides with Dako EnVi-
sion+ System-HRP labeled polymer anti-rabbit at room
temperature, and then we rinsed, incubated and counter-
stained with Harris' hematoxylin.
An Aperio ScanScope AT (Leica Biosystems, Inc., Vista,
CA, USA) digitized the slides, and we performed a
morphometric analysis with Definiens' Tissue Studio
(Definiens Inc., Parsippany, NJ, USA) to determine the
percentage of positively stained cells in a nonbiased method.Table 2
Serum cytokine levels after IUD placement
Markers Healthy before
IUD pg/ml (SE)
After IUD
pg/ml (SE)
Median change
[within-group p value]
pg/ml (SE)
Trans
IUD
IL-6 5.59 (1.06) 3.97 (1.49) 0.24 [.97] (0.65) 5.96
IL-8 9.24 (9.15) 9.27 (3.45) −0.72 [.24] (6.21) 9.49
IL-10 2.24 (0.54) 2.43 (0.42) −0.10 [.65] (0.43) 1.35
TNF-α 21.58 (3.24) 19.83 (2.55) −1.33 [.17] (1.59) 22.22
IFN-γ 1.73 (0.81) 1.63 (0.59) −0.25 [.37] (0.63) 1.10
IL-1β 4.04 (0.64) 4.19 (0.67) −0.53 [.21] (0.24) 2.48
We used the lowest limit of detection (LLOD) as a measure of assay sensitivity. L
above the LLODs, so we have concluded that since the analytes were readily dete2.5. Statistical analysis
We performed a nonparametric analysis since the data
distribution did not follow the normal distribution and was
nonsymmetric. As a result, we compared medians on the
original scale. We computed the p values for comparing the
markers levels before and after IUD insertion within a group
using the nonparametric Wilcoxon signed rank test. We used
the Wilcoxon rank sum method to compare the change
between the two groups.3. Results
3.1. Total participants
We enrolled a total of 17 participants in the study: 5 SOT
patients and 12 healthy patients. However, 1 of the healthy
participants was lost to follow-up, giving 11 healthy patients
with complete data.
Table 1 provides the participants' characteristics. The age
range for the healthy and transplant patients were similar,
with mean age of 27.6 years for the healthy and 29.4 years
for the transplant patients. Majority of the candidates were
nulliparous. In the healthy group, majority were white, while
in the transplant group, majority were minorities.
The type of SOTs varied. One patient had bilateral renal
transplants, two were lung transplant patients, one had a
heart transplant, and one patient was both a heart and renal
transplant recipient. Alongside this variation was the mix of
medication regimens. All five patients were on tacrolimus,
three were on prednisone, and two were on CellCept. Three
were also on antibiotics.
3.2. Serum concentration of cytokines and soluble receptors
The concentrations of the serum cytokines and soluble
receptors were variable. Given the nonsymmetric data set,
we calculated the medians for each marker before and after
IUD placement. The median change reflected the change in
the inflammatory marker levels after IUD placement.
When inspecting the changes within the groups, the
change in serum inflammatory markers went mostly
downwards for the healthy group, while there was a smallplant before
pg/ml (SE)
After IUD
pg/ml (SE)
Median change
[within-group p value]
pg/ml (SE)
Between-group
p value
(1.86) 9.57 (2.71) 1.78 [.31] (1.36) .28
(2.69) 12.35 (7.90) 2.52 [.31] (6.65) .10
(1.41) 2.18 (1.22) 0 [.63] (0.37) .46
(6.70) 25.73 (7.14) 5.85 [.06] (1.53) .01
(0.93) 1.97 (1.34) 0.61 [.13] (0.56) .02
(1.83) 2.77 (2.09) 1.41 [.31] (0.57) .03
LODs for these analytes ranged from 0.31 to 24.93. The analytes were well
ctable, the assay was sufficiently sensitive.
Table 3
Serum soluble receptor levels after IUD placement
Markers Healthy before
IUD pg/ml (SE)
After IUD
pg/ml (SE)
Median change pg/ml
(SE) [p value]
Transplant before
IUD pg/ml (SE)
After IUD pg/ml
(SE)
Median change pg/ml
(SE) [p value]
Between-group
p value
CD 14 1,849,366 (156,652) 1,847,185 (136,156) −54,378 (138,798) [.64] 2,190,542 (242,708) 1,930,168 (187,110) −32,845 (130,544) [.31] .69
sTNF-R 3559 (847) 3367 (613) −213 (741) [.70] 4753 (681) 4157 (1415) 129 (774) [.81] .69
sIL-6R 51,908 (5601) 52,797 (5509) 1839 (1802) [.58] 59,509 (6355) 61,736 (11,906) 947 (6644) [.44] .87
sIL-2R 976 (260) 898 (251) −64 (75.2) [.83] 885 (229) 916 (211) −95 (58.4) [.31] .46
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p values N.5) (Tables 2 and 3). When comparing the marker
changes between the two groups, there were three markers
worth noting: TNF-α (p=.01), IFN-γ (p=.02) and IL-1β (p=
.03) (Table 2). Fig. 1 provides a visual presentation of these
findings.
3.3. Uterine lavage
We also measured intrauterine concentrations of the
cytokines and soluble receptors. There was a marked
increase in lavage fluid levels of IL-1β, IL-6, IL-8, IL-10
and TNF-α in the control group post-IUD insertion (Table 4).
IFN-γ levels did not appear to increase. Similarly, the
transplant patients showed increased post-IUD insertion
levels of IL-1β, IL-6, IL-8 and TNF-α (pb.06–.13). The
transplant group did not exhibit an increase in post-IUD
insertion lavage levels of either IL-10 or IFN-γ. Addition-
ally, the median levels of these inflammatory cytokines were
generally lower in the transplant group than in the controls,
although the fold increase was often comparable. For
example, lavage median IL-6 levels post-IUD insertion
were nearly twice as high in the control group as in the
transplant group, but the fold increase in lavage IL-6 levels
was 52 in the control group and N100 in the transplant group.
Lavage levels of the sIL2-R, TNF-R2, sCD14 and sIL-6R
also increased post-IUD insertion both in transplant
recipients and in controls (Table 5). Median lavage levelsp=.01
Fig. 1. Serum TNF-α of healthy versus SOT.of these soluble receptors post-IUD insertion were generally
similar to the levels seen in the transplant group when
compared to the control group. In fact, the magnitude
increases seen were greater in the transplant group than in the
control group. For instance, the transplant group held a
N40-fold increase in lavage median sCD14 levels, while the
control group showed about a 3-fold increase in lavage
sCD14.
3.4. Endometrial biopsy results (pathology and immunohis-
tochemistry)
3.4.1. Pathology
A gynecologic pathologist reviewed the endometrial
biopsy samples from the first visit to rule out abnormalities.
None of the specimens showed hyperplasia or malignancy.
Majority of the endometrium samples from healthy
controls were in the proliferative phase. Three of the
specimens had inactive endometrial glands with decidua-
lized stromal cells. Two specimens showed scant weakly
secretory to inactive endometrium only. Majority of the
transplant EMB specimens showed inactive endometrial
glands with decidualized stromal cells or secretory phase
endometrium.
3.5. IHC: M1 activity
M1 activity included markers that reflect a proinflamma-
tory response. There was an increase in IHC staining for the
following markers in both groups: CD 16 and IL-8 (pb.05 for
healthy, pN.06–.13 for transplant) (Table 6). There was a
decrease in IHC staining for both groups of CD 86, IFN-γ
and TNF-α post-IUD insertion (Table 6). It is again noted
that the decrease in IHC staining was blunted for the
transplant group for the TNF-α and CD 86 when compared
to the healthy group. For the IL-6 marker, the healthy group
had a decrease in IHC staining post-IUD (p=.17), whereas
the transplant group had a small increase in staining (p=1).
3.6. IHC: M2 activity
M2 activity included markers that reflect an
anti-inflammatory state. An increase in IHC staining
occurred post-IUD for the healthy group for the following
M2 markers: arginase and CD 206 (Table 7). The trend was
opposite for the transplant group where the IHC staining
decreased post-IUD for these two markers (p values for all
changes=.44–1).
Table 4
Lavage cytokine levels after IUD placement
Markers Healthy before
IUD pg/ml (SE)
After IUD
pg/ml (SE)
Median change pg/ml
(SE) [p value]
Transplant before
IUD pg/ml (SE)
After IUD
pg/ml (SE)
Median change pg/ml
(SE) [p value]
Between-group
p value
IL-6 6.8 (5.3) 352.7 (236) 352.1 (235) [.002] 1.8 (4.6) 198 (43.3) 194 (4.07) [.06] .28
IL-8 46.5 (55) 6902.4 (1398) 6745 (1397) [.001] 40.5 (147.4) 2164.7 (608) 2112.0 (504.5) [.06] .19
IL-10 0.44 (0.30) 2.26 (0.89) 1.77 (0.95) [.02] 0.56 (0.14) 0.56 (0.37) 0.16 (0.38) [.31] .23
TNF-α 0.41 (0.93) 16.41 (8.61) 15.14 (8.64) [.005] 0.41 (0.93) 8.14 (2.19) 5.02 (2.14) [.13] .19
IFN-γ 0.29 (0.38) 0.50 (0.12) 0 (0.36) [.71] 0.52 (0.13) 0.68 (0.25) 0.00 (0.26) [.50] .33
IL-1β 2.55 (0.91) 180.6 (103.1) 180.3 (103.4) [.002] 0.56 (3.90) 40.9 (66.2) 40.3 (62.9) [.06] .46
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staining after IUD placement. The decrease was more
marked for the transplant group. The IL-10 staining was
100% before and after IUD placement for both the healthy
and transplant endometrium.
3.7. Exit survey
In the exit survey, the common side effect was irregular
bleeding. For the healthy patients, 8 of the 11 respondents
noted an increase in their bleeding since the IUD placement.
For the transplant patients, two of the five respondents noted
an increase, and the other three noted a decrease in their
bleeding since IUD placement.
The transplant patients also responded that since
receiving their IUD, their medical condition either had
remained stable or had improved. When asked about their
satisfaction towards the IUD, all transplant patients replied as
“satisfied” or “very satisfied.” For the healthy patients, 10 of
the 11 respondents were satisfied or very satisfied with their
IUD. The one person who had reported “neutral” requested
for its removal at the end of her follow-up study.4. Discussion
The main objective of this pilot study was to describe the
endometrial milieu of the SOT group. It also investigated the
healthy endometrium by looking at an array of inflammatory
markers rather than a single inflammatory marker. The other
unique feature to this project was the combination of
endometrial biopsy, serum and uterine washings for
specimen collection. The results of these entities provided
additional information that may inform future studies on the
IUD and its mechanism of action.
The reason for testing the serum was to determine if there
were any systemic inflammatory effects of the IUD.Table 5
Lavage soluble receptor levels after IUD placement
Markers Healthy before
IUD pg/ml (SE)
After IUD
pg/ml (SE)
Median change pg/ml
(SE) [p value]
Trans
IUD p
CD 14 25,590 (10,798) 76,147 (17,237) 42,655 (22,927) [.07] 1851
sTNF-R 182 (62.9) 956 (208) 424 (209) [.003] 25.5
sIL-6R 1083 (357) 1949.6 (445) 1035 (733) [.28] 161
sIL-2R 18.8 (8.5) 65.5 (26) 42.7 (31.4) [.12] 0.9Essentially, there were no notable changes in these
inflammatory markers pre- and post-IUD insertion in both
groups. Most of the markers were proinflammatory markers.
We also measured soluble receptors as they are found at
higher levels and are more readily detectable than cytokines,
which are often found at low levels in biological specimens.
We included sCD14 since it is released by activated
macrophages. Overall, it appeared that IUD insertion did
not result in any marked changes in systemic inflammation,
at least as detected by these biomarkers.
The uterine lavage results were interesting to note. The
inflammatory markers markedly increased in both groups
after IUD insertion, which was consistent with the notion
that the IUD induces a strong local inflammatory effect. The
only marker that had no median change in either group was
IFN-γ, which is associated with T-cell activation but is not
necessarily associated with inflammatory responses. We also
noticed that the majority of the median changes in the lavage
cytokine levels in the healthy group were larger compared to
those in the transplant group. In particular, we observed an
increase in the following markers for both groups: IL-6, IL-8,
IL-10, TNF-α, IL-1β, sTNF-R2. This aligned well with the
findings of Archer et al. of an increase of IL-6 and TNF-α after
IUD placement in healthy, postmenopausal women [10].
Overall, there were marked increases in median lavage
levels of most cytokines and soluble receptors in both the
transplant and control groups. Therefore, transplant recipi-
ents clearly exhibited strong local inflammatory responses
following insertion of the IUD.
We conducted immunohistochemistry staining of the
endometrial biopsy specimens to discern the subtypes of
macrophages with the IUD in place. The M2 markers
(anti-inflammatory subtype) did not predominate in the
transplant group as theorized. Arginase, CD 206 and IL-4 all
showed a decrease in median change. We had expected an
increase in these anti-inflammatory markers for the transplantplant before
g/ml (SE)
After IUD
pg/ml (SE)
Median change pg/ml
(SE) [p value]
Between-group
p value
(31,341) 76,717 (24,531) 26,783 (19,455) [.13] .95
(84.5) 590 (166) 482 (121) [.06] .53
(686) 1396 (285) 634 (463) [.31] .87
(15) 104 (37.5) 76 (27.8) [.13] .78
Table 6
M1 activity in endometrial tissue: all values below represent the percentage staining
Marker Healthy before
IUD % (SE)
After IUD
% (SE)
Median change
% (SE) [p value]
Transplant before
IUD % (SE)
After IUD
% (SE)
Median change
% (SE) [p value]
Between-group
p value
CD 16 21.7 (7.8) 51.2 (7.2) 28.5 (11.4) [.014] 15 (16.6) 36.9 (10.4) 21.6 (6.6) [.13] .46
CD 86 3.2 (1.1) 0.9 (1.7) −1.4 (2.0) [.28] 3.3 (1.0) 3.2 (0.8) −0.8 (0.8) [.63] .46
IL-6 14.2 (5.2) 7.4 (2.1) −5.0 (4.4) [.17] 21 (8.4) 21.9 (7.5) 0.9 (9.6) [1.0] .87
IL-8 2.7 (5) 15.8 (9.4) 3.1 (10.2) [.03] 2.0 (1.2) 25.4 (10.2) 24 (10.2) [.06] .40
IFN-γ 76.2 (3.9) 57.8 (7.6) −5.2 (8.6) [.03] 84.6 (10.4) 58.5 (7.6) −5.2 (8.6) [.13] .46
TNF-α 41.1 (8.6) 23.3 (7.9) −25.6 (11.1) [.21] 50.1 (17.6) 42.2 (16.6) −3.7 (13.5) [.44] .53
Using the Definiens' Tissue Studio, we performed morphometric analysis to determine the percentage of positively stained cells. Briefly, using the predefined
nuclear detection module or cell simulation module (for cytoplasmic staining) and classification tool, positive and negative cells within each tissue section were
identified. Thresholds were set to classify hematoxylin staining for nuclei and DAB staining for positive nuclei or cytoplasm.
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predominate in the healthy endometrium.CD16 and IL-8were
the only markers that increased in the healthy endometrium.
Additional results from this study included the high
satisfaction and acceptability of the IUD as their form of
contraception for the SOT patients. The irregular bleeding
and cramping were common effects after IUD placement
in both groups. In their exit survey, the transplant patients
also noted no complications in their disease since the
IUD placement.
There were several limitations to this study. It was a small
studywhere recruitment of the transplant patientswas difficult,
as recruitment was impaired by insurance and logistical
barriers. Another limitation was the nonuniformity of
immunosuppressant regimens given that the SOT participants
had different types of transplants. The follow-up time was not
long term aswell. In addition, when using a fluid wash, studies
have shown highly variable concentrations of cytokines.
[15,16] We did not adjust or correct for total protein
concentration. However, to minimize variability, we used a
fixed volume of saline for the lavages and used the same
collection protocol for all cases. These limitations will help
inform the next steps in formulating a larger study investigat-
ing this same patient population.
In conclusion, our study has peered into the endometrium
of the SOT patient. Although this pilot study could not
discern significant differences between the healthy and
transplant endometrium with an LNG-IUD in place, it at leastTable 7
M2 activity in endometrial tissue: all values below are percentage staining
Markers Healthy before IUD
% (SE)
After IUD
% (SE)
Median change
% (SE) [p value]
Tra
IU
Arginase 10.2 (2.6) 12.9 (2.8) 3.0 (4.2) [.83] 11
CD 206 12.1 (6.8) 13.8 (5.3) 4.6 (9.9) [1.0] 16
IL-4 64.8 (7.2) 53.3 (4.3) −8.4 (8.1) [.37] 7
IL-10a 100 100 0 10
Using the Definiens' Tissue Studio, we performed morphometric analysis to deter
nuclear detection module or cell simulation module (for cytoplasmic staining) and c
identified. Thresholds were set to classify hematoxylin staining for nuclei and DA
a Analysis not conducted.allowed us to recognize certain patterns that align with prior
studies. Serum results reflected that the LNG-IUD does not
exhibit a systemic inflammatory effect, whereas the uterine
lavage results correlated to the idea that the IUD is inducing a
local inflammatory effect. In addition, for the lavage, the
inflammatory marker increase may be blunted in the
transplant group compared to the healthy controls, but
there was still a marked increase in local inflammation seen
in the transplant recipients. These preliminary findings will
help power a larger study that can look into the safety and
effectiveness of the IUD in this special patient population.
This study has, at the very least, started us on the pathway of
reassurance that the IUD is a feasible contraceptive option
for the transplant patient.Acknowledgments
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